Biotechnology company Scope Fluidics debuts on main floor of WSE
14:38
On 18 February, the biotechnology company Scope Fluidics S.A. made its debut on the main market of the Warsaw Stock Exchange (WSE). The company, which carries out projects in the field of diagnostics and healthcare, has moved to the main trading floor from NewConnect.
"We want to share our successes with our shareholders," Piotr Garstecki, CEO of Scope Fluidics, argued during the IPO.
"This is the 418th company listed on the Warsaw Stock Exchange and also the 12th in the biotechnology sector," Monika Gorgoń, board member of the Warsaw Stock Exchange, reported.
Scope Fluidics has been developing technology projects in the field of diagnostics and healthcare since 2010. The company's business concept is to implement innovative ideas within the framework of created special-purpose vehicles.
